Velagliflozin

Velagliflozin is a pharmaceutical drug used in the treatment of type 2 diabetes. It belongs to the class of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors, which work by preventing the kidneys from reabsorbing glucose back into the blood, thereby promoting the excretion of glucose in urine.

Mechanism of Action[edit | edit source]

Velagliflozin inhibits the sodium-glucose co-transporter 2 (SGLT2) in the proximal renal tubules, reducing the reabsorption of glucose from the renal tubules into the bloodstream. This leads to an increase in glucose excretion in the urine, which in turn lowers blood glucose levels.

Clinical Use[edit | edit source]

Velagliflozin is used in the management of type 2 diabetes. It is often used in combination with other antidiabetic medications such as metformin or insulin when these alone do not provide adequate glycemic control.

Side Effects[edit | edit source]

Common side effects of Velagliflozin include urinary tract infections, genital yeast infections, and increased urination. Rare but serious side effects include ketoacidosis, a serious condition that can occur if your body produces high levels of blood acids called ketones.

Contraindications[edit | edit source]

Velagliflozin is contraindicated in patients with severe renal impairment, end-stage renal disease, or dialysis. It is also contraindicated in patients with a history of hypersensitivity to Velagliflozin or any of its components.

Drug Interactions[edit | edit source]

Velagliflozin may interact with other medications, including diuretics, insulin, and other antidiabetic drugs. It is important to inform your healthcare provider of all the medications you are currently taking.

File:Velagliflozin.png

Chemical structure of Velagliflozin